Dengue – Pipeline Review, 2019

Dengue is an expeditious emerging pandemic-prone viral infection worldwide. Dengue largely affects the poor urban areas, suburbs, and countryside but also affects the tropical and subtropical regions. Dengue is a mosquito-borne disease caused by a family of Flaviviridae virus and spread through a vector, Aedes mosquitoes causing a severe flu-like illness, and sometimes leading to lethal complications. Symptoms of dengue include high fever accompanied by severe headache, nausea, vomiting, muscle & joint pain and rashes.

Currently, there is a lack of specific treatment for dengue, but early detection and access to proper medical care reduces the fatality rates. For milder forms, prevention of dehydration, medications including painkillers, non-steroidal anti-inflammatory drugs, and other interventions are provided. Acetaminophen is used to reduce pain and fever in dengue patients.

According to World Health Organization (WHO), increase in dengue cases is being reported in regions of Western Pacific, Africa, and America in 2019, when compared to 2017-2018, emphasizing the need for novel therapy. Pharmaceutical companies, along with various research institutes, are focusing on studying and developing novel vaccines for the treatment of dengue. For instance; TDV, which is being studied by Takeda Pharmaceutical Company Limited is currently in phase 3 clinical trials for the study of safety and immunogenicity in dengue patients of non-endemic areas.

At present, around 54% of the pipeline candidates for dengue are in the phase-1 clinical stage. Maximum studies are sponsored by research institutes.

Report Description

The report on ‘Dengue – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Dengue. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Dengue.

The report on ‘Dengue – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases, and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Dengue.


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for Dengue.


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary